Identifying Key MA-methylated LncRNAs and Genes Associated with Neural Tube Defects Integrative MeRIP and RNA Sequencing Analyses
Overview
Authors
Affiliations
N-methyladenosine (mA) is a common post-transcriptional modification of messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs). However, mA-modified lncRNAs are still largely unexplored. This study aimed to investigate differentially mA-modified lncRNAs and genes involved in neural tube defect (NTD) development. Pregnant Kunming mice (9-10 weeks of age) were treated with retinoic acid to construct NTD models. mA levels and methyltransferase-like 3 () expression were evaluated in brain tissues of the NTD models. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) were performed on the NovaSeq platform and Illumina HiSeq 2,500 platform, respectively. Differentially mA-methylated differentially expressed lncRNAs (DElncRNAs) and differentially expressed genes (DEGs) were identified, followed by GO biological process and KEGG pathway functional enrichment analyses. Expression levels of several DElncRNAs and DEGs were evaluated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for validation. mA levels and expression levels were significantly lower in the brain tissues of the NTD mouse model than in controls. By integrating MeRIP-seq and RNA-seq data, 13 differentially mA-methylated DElncRNAs and 170 differentially mA-methylated DEGs were identified. They were significantly enriched in the Hippo signaling pathway and mannose-type -glycan biosynthesis. The qRT-PCR results confirmed the decreased expression levels of lncRNAs, such as Mir100hg, Gm19265, Gm10544, and Malat1, and genes, such as , , and , in the NTD group. -mediated mA modifications may be involved in NTD development. In particular, decreased expression levels of Mir100hg, Gm19265, Gm10544, Malat1, , , and may contribute to the development of NTD.
Research progress on ultrasound and molecular markers for prenatal diagnosis of neural tube defects.
Yin J, Wang Y, Wang S, Li G, Gu H, Chen L Heliyon. 2024; 10(16):e36060.
PMID: 39247260 PMC: 11378877. DOI: 10.1016/j.heliyon.2024.e36060.
Advances in brain epitranscriptomics research and translational opportunities.
Zhang F, Ignatova V, Ming G, Song H Mol Psychiatry. 2023; 29(2):449-463.
PMID: 38123727 PMC: 11116067. DOI: 10.1038/s41380-023-02339-x.
A concise review on the role of MIR100HG in human disorders.
Ghafouri-Fard S, Harsij A, Farahzadi H, Hussen B, Taheri M, Mokhtari M J Cell Mol Med. 2023; 27(16):2278-2289.
PMID: 37487022 PMC: 10424294. DOI: 10.1111/jcmm.17875.